Published on: December 19, 2014

The FDA finally presses send

The US FDA yesterday published “final guidance” around the implementation of a new pre-clinical drug trial data standard, known as SEND. This has the potential to drive significant software (and services) revenue for Instem over coming years as pharmaceutical companies and their ecosystems scramble to implement platforms in time to meet the now-imposed deadline. We make no changes to our forecasts, but adding this to yesterday morning’s contract win with WIL Research, Instem has had a good week.

Related Content